Haemonetics Wins CE Mark for VASCADE MVP XL
The venous closure system is now approved for sale in the European Union under the EU-MDR.
Updated on Nov. 19, 2026 in Healthcare

Haemonetics has received CE Mark certification for its VASCADE MVP XL venous vascular closure system, which is designed to close femoral venous access sites percutaneously. The first European procedures with the device were performed in October 2026 at sites in Hamburg, Milan, and London.
Why it matters
The certification expands Haemonetics' vascular closure portfolio in Europe, where the company expects the device to significantly broaden its impact and commercial momentum in electrophysiology and interventional cardiology. It also gives European clinicians a closure option for larger-bore venous sheaths.
The VASCADE MVP XL uses 58% more collagen and a disc 9% larger than the VASCADE MVP, and is indicated for 10-12F inner diameter sheaths with a 15F maximum outer diameter. Clinical outcome data from the first European procedures has not been disclosed.
The players
Haemonetics Corporation
Haemonetics is a Boston-based medical technology company that produces blood management and surgical products, and it has built a vascular closure portfolio spanning the VASCADE and VASCADE MVP systems.
The details
The VASCADE MVP XL closes femoral venous access sites using a proprietary collapsible disc and a resorbable collagen plug to achieve haemostasis. The first European procedures were performed at Asklepios Clinic Altona in Hamburg, Centro Cardiologico Monzino in Milan, and Cromwell Hospital in London.
Timeline
October 2026: First European procedures with the VASCADE MVP XL system were performed.
November 19, 2026: Haemonetics announced the CE Mark certification.
Market Landscape
The VASCADE MVP XL extends the existing VASCADE MVP mid-bore platform to larger sheaths, using 58% more collagen and a 9% larger disc. The launch adds to Haemonetics' EU-MDR-compliant vascular closure lineup alongside the smaller-bore VASCADE system.
For patients undergoing procedures that use larger venous sheaths, the device offers an additional closure option once it is adopted by hospitals in the European Union. Clinicians and hospital purchasing teams will decide how quickly the system enters routine use.
The takeaway
Medical device makers are extending proven closure platforms to larger access sites, and clinical adoption will depend on real-world procedure results that are still to come. Hospitals evaluating vascular closure options should weigh sheath size compatibility against the device's documented specifications.
Further reading
For broader coverage of device makers and hospital supply, see the Healthcare section.
Source note: This article includes information reported by Pharmabiz.



